Stay updated on Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedThe page now includes a new entry: Revision: v3.3.3. The footer link 'HHS Vulnerability Disclosure' and the older 'Revision: v3.3.2' have been removed.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedRecord History shows a new metadata revision (Revision: v3.3.2) added and an older revision (Revision: v3.2.0) removed; this reflects version metadata rather than content changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check48 days agoChange Detected- Removed a prominent notice stating that information on the site may not be up to date due to government funding lapses and that the NIH Clinical Center is open, with links to cc.nih.gov and opm.gov for status updates.SummaryDifference0.3%

- Check63 days agoChange DetectedThe Record History for NCT03631199 now shows additional history entries, reflecting newer submissions and status updates.SummaryDifference0.0%

- Check91 days agoChange Detected- Added a government-operating-status notice and a link to operating status information, signaling potential delays in processing and inquiries. - Updated version to v3.2.0 and removed the previous v3.1.0 reference.SummaryDifference7%

- Check99 days agoChange DetectedUpdate to page version and study-status/locations; old version and revision removed. New v3.1.0 with date 2025-09-22; previous v3.0.2 and date 2025-09-10 removed.SummaryDifference0.8%

Stay in the know with updates to Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page.